Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$104.10 -2.0%	$106.45	$72.02 ▼ $139.13	$5.13B	0.47	677,321 shs	425,883 shs
BPMC Blueprint Medicines	$127.96 -0.2%	$100.02	$73.04 ▼ $128.34	$8.26B	0.84	1.20 million shs	4.73 million shs
MESO Mesoblast	$11.78 -3.1%	$11.22	$5.78 ▼ $22.00	$1.51B	2.41	273,267 shs	123,530 shs
SRPT Sarepta Therapeutics	$36.18 -3.0%	$46.25	$34.10 ▼ $173.25	$3.56B	0.61	1.81 million shs	3.19 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	0.00%	-6.98%	-2.91%	-14.61%	+45.49%
BPMC Blueprint Medicines	0.00%	+0.09%	+28.62%	+42.84%	+20.56%
MESO Mesoblast	0.00%	-0.08%	-1.42%	-13.06%	+64.07%
SRPT Sarepta Therapeutics	0.00%	-15.88%	+2.58%	-62.77%	-69.84%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AXSM Axsome Therapeutics	4.6819 of 5 stars	4.5	2.0	4.5	1.8	4.2	0.6
BPMC Blueprint Medicines	1.0496 of 5 stars	2.2	2.0	0.0	2.2	0.8	0.6
MESO Mesoblast	2.2798 of 5 stars	3.5	3.0	0.0	2.1	0.8	0.6
SRPT Sarepta Therapeutics	4.7137 of 5 stars	4.4	2.0	4.2	2.6	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXSM Axsome Therapeutics	3.06	Buy	$172.33	65.55% Upside
BPMC Blueprint Medicines	2.32	Hold	$129.35	1.09% Upside
MESO Mesoblast	3.00	Buy	$18.00	52.80% Upside
SRPT Sarepta Therapeutics	2.87	Moderate Buy	$122.61	238.89% Upside

Current Analyst Ratings Breakdown

Latest MESO, SRPT, BPMC, and AXSM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	AXSM Axsome Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$193.00 ➝ $186.00
6/10/2025	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$180.00
6/9/2025	AXSM Axsome Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$153.00 ➝ $150.00
6/6/2025	SRPT Sarepta Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sector Perform ➝ Sector Outperform	$80.00
6/5/2025	BPMC Blueprint Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$102.00 ➝ $129.00
6/5/2025	BPMC Blueprint Medicines	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$88.00 ➝ $129.00
6/4/2025	BPMC Blueprint Medicines	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold	$83.00 ➝ $129.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$132.00
6/3/2025	AXSM Axsome Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$185.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXSM Axsome Therapeutics	$432.16M	11.86	N/A	N/A	$1.18 per share	88.22
BPMC Blueprint Medicines	$562.12M	14.70	N/A	N/A	$4.67 per share	27.40
MESO Mesoblast	$5.67M	265.47	N/A	N/A	$4.21 per share	2.80
SRPT Sarepta Therapeutics	$2.23B	1.59	N/A	N/A	$9.19 per share	3.94

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXSM Axsome Therapeutics	-$287.22M	-$5.77	N/A	36.91	N/A	-74.47%	-223.51%	-39.88%	8/4/2025 (Estimated)
BPMC Blueprint Medicines	-$67.09M	-$2.47	N/A	196.86	N/A	-13.19%	-77.49%	-20.84%	7/30/2025 (Estimated)
MESO Mesoblast	-$87.96M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/29/2025 (Estimated)
SRPT Sarepta Therapeutics	-$535.98M	-$2.69	28.94	3.31	N/A	7.43%	11.00%	3.35%	8/6/2025 (Estimated)

Latest MESO, SRPT, BPMC, and AXSM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/6/2025	Q1 2025	SRPT Sarepta Therapeutics	$2.20	-$3.42	-$5.62	-$4.60	$685.75 million	$744.86 million
5/1/2025	Q1 2025	BPMC Blueprint Medicines	-$0.42	-$0.74	-$0.32	$0.01	$158.31 million	$149.41 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
BPMC Blueprint Medicines	N/A	N/A	N/A	N/A	N/A
MESO Mesoblast	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXSM Axsome Therapeutics	3.22	2.11	2.04
BPMC Blueprint Medicines	1.15	2.85	2.80
MESO Mesoblast	0.21	1.18	1.18
SRPT Sarepta Therapeutics	0.93	3.84	3.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXSM Axsome Therapeutics	81.49%
BPMC Blueprint Medicines	N/A
MESO Mesoblast	1.43%
SRPT Sarepta Therapeutics	86.68%

Insider Ownership

Company	Insider Ownership
AXSM Axsome Therapeutics	22.30%
BPMC Blueprint Medicines	4.21%
MESO Mesoblast	18.80%
SRPT Sarepta Therapeutics	7.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXSM Axsome Therapeutics	380	49.24 million	37.84 million	Optionable
BPMC Blueprint Medicines	640	64.58 million	61.22 million	Optionable
MESO Mesoblast	80	127.78 million	103.17 million	Optionable
SRPT Sarepta Therapeutics	840	98.28 million	88.17 million	Optionable

MESO, SRPT, BPMC, and AXSM Headlines

Recent News About These Companies

Sarepta reports second case of liver failure death after its gene therapy treatment

June 15 at 2:06 AM | reuters.com

Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne

June 15 at 1:00 AM | businesswire.com

Tobam Has $2.41 Million Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

June 13 at 6:23 AM | marketbeat.com

Assenagon Asset Management S.A. Raises Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

June 13 at 4:35 AM | marketbeat.com

GAMMA Investing LLC Purchases 39,991 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

June 13 at 3:17 AM | marketbeat.com

Sarepta Therapeutics’ (SRPT) Rating Downgrade Dents Share Price

June 11, 2025 | yahoo.com

1 Unprofitable Stock for Long-Term Investors and 2 to Ignore

June 10, 2025 | uk.finance.yahoo.com

Sarepta Therapeutics (NASDAQ:SRPT) Trading Down 6.1% - Should You Sell?

June 9, 2025 | marketbeat.com

Sarepta Therapeutics (NASDAQ:SRPT) Upgraded to Sector Outperform at Scotiabank

June 9, 2025 | americanbankingnews.com

BMO Capital Remains a Buy on Sarepta Therapeutics (SRPT)

June 8, 2025 | theglobeandmail.com

Sarepta Therapeutics (NasdaqGS:SRPT) Gains 19% Over Past Month Following Japan Approval

June 8, 2025 | finance.yahoo.com

Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Up 8% - Should You Buy?

June 8, 2025 | americanbankingnews.com

July 25th Options Now Available For Sarepta Therapeutics (SRPT)

June 7, 2025 | nasdaq.com

Sarepta Therapeutics’ gene therapy to treat limb girdle muscular dystrophy type 2E/R4 gets US FDA platform technology designation

June 7, 2025 | pharmabiz.com

Sarepta upgraded at Scotiabank on attractive risk reward setup

June 7, 2025 | msn.com

Scotiabank Upgrades Sarepta Therapeutics (SRPT)

June 7, 2025 | msn.com

Sarepta Therapeutics Approves Amendments at Annual Meeting

June 6, 2025 | tipranks.com

Sarepta Therapeutics (NASDAQ:SRPT) Trading Up 8% - Here's Why

June 6, 2025 | marketbeat.com

Sarepta Therapeutics (SRPT) Upgraded by Scotiabank with Sector Outperform Rating | SRPT Stock News

June 6, 2025 | gurufocus.com

Scotiabank Upgrades Sarepta Therapeutics (NASDAQ:SRPT) to "Sector Outperform"

June 6, 2025 | marketbeat.com

Sarepta Wins FDA’s Platform Technology Designation, Marking ‘Critical Shift’ in Gene Therapy Development

June 6, 2025 | biospace.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MESO, SRPT, BPMC, and AXSM Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

$104.10 -2.15 (-2.02%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$104.08 -0.02 (-0.02%)

As of 06/13/2025 06:10 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Blueprint Medicines NASDAQ:BPMC

$127.96 -0.25 (-0.19%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$128.38 +0.42 (+0.32%)

As of 06/13/2025 05:27 PM Eastern

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Mesoblast NASDAQ:MESO

$11.78 -0.38 (-3.13%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$11.77 -0.01 (-0.08%)

As of 06/13/2025 07:20 PM Eastern

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Sarepta Therapeutics NASDAQ:SRPT

$36.18 -1.13 (-3.03%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$36.43 +0.25 (+0.69%)

As of 06/13/2025 08:00 PM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time